| BIOMARIN PHARMACEUTICAL INC. |
| USA |
| Gesundheit |
| US09061G1013 / 924801 |
| BM8 (Frankfurt) / BMRN (NASDAQ) |
| FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN |
| - |
| https://www.biomarin.com/ |
|
Biomarin Pharmaceutical Inc. is a global biotechnology company specializing in therapies for rare, genetically defined diseases. The company focuses on developing and commercializing targeted treatments that address the underlying biology of serious ..
>Volltext.. |
| 10910.01 Mio. EUR |
| 13854.99 Mio. EUR |
| 2984.05 Mio. EUR |
| 684.13 Mio. EUR |
| 62.99 Mio. EUR |
| 0.33 EUR |
| 3640.89 Mio. EUR |
| 754.48 Mio. EUR |
| 739.87 Mio. EUR |
| 0.53 |
| 17.26% |
| -88.55% |
| - |
| - |
| - |
| - |
| BIOMARIN |
| 31.08.26 |
|